ID   CALDOX
AC   CVCL_RR30
DR   Wikidata; Q54808416
RX   PubMed=23122841;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1110 ! CAL-51
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 5
//
RX   PubMed=23122841; DOI=10.1016/j.bcp.2012.10.020;
RA   Raguz S., Adams C., Masrour N., Rasul S., Papoutsoglou P., Hu Y.-H.,
RA   Cazzanelli G., Zhou Y., Patel N., Coombes R.C., Yague E.;
RT   "Loss of O(6)-methylguanine-DNA methyltransferase confers collateral
RT   sensitivity to carmustine in topoisomerase II-mediated doxorubicin
RT   resistant triple negative breast cancer cells.";
RL   Biochem. Pharmacol. 85:186-196(2013).
//